関連する実験動画
Updated: Jul 11, 2026

14:57
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
アンサンブルベースの受容体モデルによって発見されたMDM2-p53相互作用の小分子阻害剤
Anna L Bowman1, Zaneta Nikolovska-Coleska, Haizhen Zhong
1Department of Medicinal Chemistry and the Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Journal of the American Chemical Society
|October 2, 2007
まとめ
研究者らは,柔軟なタンパク質構造法を使用して,MDM2-p53の相互作用を標的とした新しい小分子阻害剤を発見しました. このアプローチは,薬剤発見におけるタンパク質-タンパク質相互作用の阻害のための強力な化合物を効率的に特定します.
科学分野:
- 薬用化学 薬用化学について
- 構造生物学 構造生物学とは
- ドラッグ・ディスカバリー・ドリッグ・ディスカバリー・ドリッグ・ディスカバリー・ドリッグ・ディスカバリー
背景:
- MDM2-p53の相互作用は,がん治療の重要な標的である.
- タンパク質とタンパク質の相互作用のための小分子阻害剤の開発は,重要な課題を提示します.
研究 の 目的:
- ヒトのMDM2-p53相互作用の新しい非ペプチド小分子阻害剤を特定する.
- タンパク質とタンパク質の相互作用の阻害剤を発見するための多重タンパク質構造 (MPS) 方法の検証.
主な方法:
- 多重タンパク質構造 (MPS) 方法を活用し,受容体ベースの薬理型モデルにタンパク質の柔軟性を組み込みました.
- インジケート・フィット・ドッキング・プロトコルを使用して,阻害剤結合モードを分析した.
- 特定された阻害剤の実験的検証.
主要な成果:
- 5つの新しい小分子阻害剤を新しい基板で特定しました.
- 最も強力な阻害剤は,110 +/- 30 nMのKiを示した.
- ドッキング研究は,阻害剤がp53結合残基を模倣し,結合裂け目を効果的に占め,追加の水素結合の機会を利用することを示唆しました.
結論:
- MPS技術は,構造ベースの薬剤発見の有望な進歩です.
- この方法は,タンパク質とタンパク質の相互作用の強力な阻害物質を発見するために,化学的空間を効率的に探求します.
- MPSで発見された阻害剤の実験的検証を実証し,その実用的な有用性を強調した.
関連する概念動画
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Covalently Linked Protein Regulators
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
These groups modify specific amino acids in a protein.
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

